NFE2L2 and diabetic kidney disease: Furthermore, pharmacological activation of Nfe2l2 in the streptozotocin (STZ) diabetic mouse model has been shown to attenuate the characteristics of diabetic nephropathy, including reduced albuminuria, renal hypertrophy and thickening of the basement membrane [51].